Oophorectomy (Ovarian Removal) in India
Get Oophorectomy (Ovarian Removal) at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.
Oophorectomy (Ovarian Removal) in UAE
Oophorectomy (Ovarian Removal) at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.
Overview
Oophorectomy — the surgical removal of one or both ovaries — is performed to treat conditions ranging from ovarian cancer and endometriosis to benign cysts and hereditary BRCA1/BRCA2-related cancer risk reduction, with reported procedural success rates exceeding 95% at high-volume centers. GAF Healthcare connects international patients with JCI- and NABH-accredited hospitals in India and JCI- and DHA-accredited facilities in Dubai and Abu Dhabi, where board-certified gynecologic surgeons perform laparoscopic, robotic-assisted, and open oophorectomy using the latest minimally invasive platforms. Patients traveling through GAF Healthcare benefit from end-to-end coordination — from e-Medical visa facilitation and pre-operative diagnostics to post-discharge rehabilitation planning — at a fraction of the cost available in Western healthcare systems.
Hospital Stay: 1–3 days (laparoscopic/robotic); 3–5 days (open/oncologic cases) • Total Stay in Country (Fit-to-Fly): 2–3 weeks for minimally invasive procedures; 4–6 weeks for open or oncologic oophorectomy • Success Rate: 95–98%
What Is It?
The ovaries are paired endocrine and reproductive organs responsible for oogenesis, estrogen and progesterone synthesis, and the regulated hormonal feedback that governs the menstrual cycle, bone density, cardiovascular health, and cognitive function. Pathological conditions including epithelial ovarian carcinoma (EOC), borderline tumors, endometrioma, polycystic ovarian disease refractory to medical management, and benign or malignant adnexal masses may necessitate unilateral oophorectomy (removal of one ovary) or bilateral oophorectomy (removal of both ovaries). When bilateral oophorectomy is performed premenopausally, it induces surgical menopause — an abrupt cessation of ovarian hormone production — producing vasomotor symptoms, accelerated bone loss (osteoporosis risk increases 2–3 fold within five years), elevated cardiovascular risk, and potential cognitive sequelae; meticulous pre-operative counseling and post-operative hormone replacement therapy (HRT) planning are therefore integral to the standard of care.
The global standard of care has shifted decisively toward minimally invasive approaches. Conventional multiport laparoscopic oophorectomy, single-incision laparoscopic surgery (SILS), and robotic-assisted laparoscopic oophorectomy using the da Vinci Xi or Versius platforms now account for over 80% of elective cases at high-volume centers. These approaches deliver equivalent oncologic outcomes to open surgery while reducing intraoperative blood loss, shortening hospital stay to 1–3 days, and enabling a return to normal activities within 2–4 weeks. For malignant disease, oophorectomy is frequently combined with hysterectomy, bilateral salpingo-oophorectomy (BSO), pelvic lymphadenectomy, and omentectomy as part of a comprehensive cytoreductive staging procedure guided by FIGO (International Federation of Gynecology and Obstetrics) criteria.
India and the UAE have emerged as premier destinations for international patients seeking oophorectomy. Indian tertiary centers — particularly in Mumbai, Chennai, Delhi, Hyderabad, and Bengaluru — process among the highest volumes of gynecologic oncology cases in Asia, producing surgical teams with extraordinary subspecialty depth. UAE facilities in Dubai Healthcare City and Abu Dhabi offer JCI-accredited environments with English-language care, premium amenities, and proximity to Europe, Africa, and the Middle East. GAF Healthcare curates access to verified, credentialed surgeons at top-tier facilities in both destinations, ensuring patients receive evidence-based care aligned with NCCN, ESMO, and RCOG clinical guidelines.
Candidates
• CONFIRMED SURGICAL CANDIDATES:
• Women diagnosed with epithelial ovarian carcinoma (EOC), germ cell tumors, or sex cord-stromal tumors requiring surgical staging or debulking
• Patients with BRCA1 or BRCA2 pathogenic variants who have completed childbearing and elect risk-reducing salpingo-oophorectomy (RRSO); recommended between ages 35–40 (BRCA1) and 40–45 (BRCA2) per NCCN guidelines
• Symptomatic endometrioma (≥3 cm) or complex adnexal cysts with malignant features on imaging (elevated CA-125, solid components, internal vascularity on Doppler)
• Recurrent ovarian torsion or torsion with non-viable ovarian tissue confirmed intraoperatively
• Benign ovarian tumors (dermoid cysts/teratomas, cystadenomas) causing pain, pressure symptoms, or complications
• Ectopic pregnancy involving the ovary unresponsive to methotrexate therapy
• Hormone-sensitive metastatic breast cancer or endometrial cancer requiring surgical oophorectomy for ovarian suppression
• Severe, refractory pelvic pain secondary to polycystic ovary syndrome (PCOS) or endometriosis unresponsive to GnRH agonist therapy, combined oral contraceptives, and surgical cystectomy
• REQUIRED PRE-OPERATIVE DIAGNOSTICS:
• Transvaginal ultrasound (TVUS) with color Doppler — first-line imaging for adnexal mass characterization
• Contrast-enhanced MRI of the pelvis — for complex or indeterminate masses; superior soft-tissue resolution
• PET-CT scan — indicated in suspected malignancy for staging, nodal mapping, and detecting occult peritoneal deposits
• Serum tumor markers: CA-125, HE4, CEA, AFP, LDH, inhibin B (tailored to histologic suspicion)
• ROMA (Risk of Ovarian Malignancy Algorithm) score calculation using CA-125 + HE4
• Complete blood count (CBC), comprehensive metabolic panel (CMP), coagulation profile (PT/INR/aPTT)
• Electrocardiogram (ECG) and 2D echocardiogram (ECHO) for patients ≥40 years or with cardiac history
• Pulmonary function tests (PFTs) if indicated by anesthesia risk assessment
• BRCA1/BRCA2 genetic testing and formal genetic counseling for high-risk patients
• Bone mineral density (DEXA scan) — baseline recommended pre-operatively for premenopausal patients undergoing bilateral oophorectomy
• Fertility preservation consultation (oocyte or embryo cryopreservation) for premenopausal patients with unilateral disease who wish to preserve reproductive options
• CONTRAINDICATIONS / RELATIVE CONTRAINDICATIONS:
• Uncorrected coagulopathy (INR >1.5 without bridging strategy)
• Severe cardiopulmonary compromise precluding general anesthesia or Trendelenburg positioning (relevant to laparoscopic approach)
• Active pelvic infection or sepsis — surgery deferred until infection controlled
• Pregnancy (oophorectomy during pregnancy carries significant fetal risk; individualized risk-benefit assessment required)
• Unresectable metastatic disease where debulking would not achieve optimal cytoreduction (<1 cm residual)
• Patient refusal after thorough informed consent including discussion of surgical menopause implications
Procedure
APPROACH 1 — CONVENTIONAL MULTIPORT LAPAROSCOPIC OOPHORECTOMY The gold-standard minimally invasive technique for benign and selected malignant adnexal disease. Three to four ports (5–12 mm) are placed in the abdomen; the surgeon uses a 10 mm 0° or 30° high-definition laparoscope, monopolar and bipolar energy devices (LigaSure, Harmonic scalpel), and an endoscopic retrieval bag (Endobag) to excise the ovary without spillage of cyst contents — a critical oncologic safety measure. CO₂ pneumoperitoneum is maintained at 12–15 mmHg. Estimated blood loss is typically <100 mL. Operative time: 45–90 minutes. Hospital stay: 1–2 days.
APPROACH 2 — SINGLE-INCISION LAPAROSCOPIC SURGERY (SILS / LESS) A technique where all instruments are introduced through a single 2–3 cm umbilical incision using a multichannel port (e.g., SILS Port, GelPOINT). Offers superior cosmesis (effectively scarless) and equivalent safety compared to multiport laparoscopy in experienced hands. Particularly favored for younger patients undergoing unilateral oophorectomy for benign conditions such as dermoid cysts or endometrioma.
APPROACH 3 — ROBOTIC-ASSISTED LAPAROSCOPIC OOPHORECTOMY (RALO) Performed using the da Vinci Xi Surgical System or CMR Surgical Versius platform. The robotic approach provides 10x magnified three-dimensional (3D-HD) visualization, EndoWrist instrumentation with 7 degrees of freedom, and tremor filtration — enabling precise dissection in deep or narrow pelvic spaces, superior control at the infundibulopelvic ligament, and reduced risk of inadvertent ureteral or vascular injury. Particularly advantageous in cases with dense adhesions from prior endometriosis, previous pelvic surgery, or in patients with a BMI >35. Operative time: 60–120 minutes. Hospital stay: 1–2 days. Available at flagship centers in Mumbai, Chennai, Gurugram (India) and Cleveland Clinic Abu Dhabi, Mediclinic City Hospital Dubai (UAE).
APPROACH 4 — OPEN (LAPAROTOMY) OOPHORECTOMY Indicated for advanced-stage ovarian malignancy requiring cytoreductive surgery, cases where laparoscopic conversion is necessitated intraoperatively (hemorrhage, dense adhesions, failed visualization), or when oophorectomy is performed as a component of radical hysterectomy with pelvic lymph node dissection. A vertical midline or Pfannenstiel incision is made; the surgeon performs meticulous dissection of the ovarian pedicles, securing the infundibulopelvic (IP) ligament and utero-ovarian ligament with absorbable sutures or surgical staplers. Estimated blood loss: 150–500 mL. Hospital stay: 3–5 days. Recovery: 4–6 weeks.
APPROACH 5 — CYTOREDUCTIVE SURGERY (DEBULKING) FOR OVARIAN CANCER For FIGO Stage III–IV epithelial ovarian carcinoma, primary debulking surgery (PDS) aims for optimal cytoreduction (residual disease <1 cm, ideally R0 — no visible residual tumor). The procedure combines bilateral salpingo-oophorectomy, total hysterectomy, omentectomy, peritoneal stripping, and selective pelvic/para-aortic lymphadenectomy. Interval debulking surgery (IDS) is employed when primary disease burden precludes upfront R0 resection; patients receive 3 cycles of neoadjuvant chemotherapy (carboplatin + paclitaxel) before surgery. Hyperthermic intraperitoneal chemotherapy (HIPEC) — delivery of heated cisplatin directly into the peritoneal cavity at the time of cytoreduction — is offered at select high-volume centers as per OVHIPEC-1 trial evidence.
APPROACH 6 — RISK-REDUCING SALPINGO-OOPHORECTOMY (RRSO) FOR BRCA CARRIERS A prophylactic bilateral salpingo-oophorectomy (BSO) performed laparoscopically in BRCA1/BRCA2 mutation carriers. Evidence demonstrates RRSO reduces ovarian cancer risk by 80–96% and breast cancer risk by 50% in BRCA1 carriers when performed before natural menopause. The procedure includes removal of the fallopian tubes (as the fimbriated end is implicated in serous carcinogenesis), systematic peritoneal washings for cytology, and careful pathologic sectioning of the entire specimen using the SEE-FIM (Sectioning and Extensively Examining the FIMbriated end) protocol to detect occult serous tubal intraepithelial carcinoma (STIC).
Cost of Oophorectomy (Ovarian Removal): India vs. UAE
The cost of oophorectomy varies significantly based on the surgical approach (laparoscopic, robotic, or open), whether the procedure is unilateral or bilateral, the presence of malignancy requiring staging, and the tier of hospital and surgeon chosen. India offers world-class gynecologic surgical expertise at costs 50–65% lower than equivalent facilities in the UAE, while the UAE provides premium hospitality, multilingual care teams, and straightforward access for patients traveling from Europe, Africa, and the GCC region. Both destinations offer JCI-accredited institutions with internationally trained subspecialty surgeons. All estimates below are in USD and cover the primary surgical episode; adjuvant chemotherapy (if indicated for malignancy) is quoted separately.
| Destination | Estimated Cost (USD) | Key Advantage |
|---|---|---|
| India | $2,500 – $7,000 | ~57% less than the UAE |
| UAE (Dubai/Abu Dhabi) | $6,000 – $16,000 | Premium care, JCI/DHA accredited |
Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.
Recovery & Aftercare
PHASE 1 — INITIAL CONSULTATION & PRE-TRAVEL PREPARATION (2–4 weeks before travel)
• Submit medical records, imaging (TVUS, MRI, PET-CT), and tumor marker results to GAF Healthcare's medical coordination team
• Receive a formal Second Opinion Report from the assigned gynecologic surgeon within 48–72 hours
• Finalize treatment plan (laparoscopic vs. robotic vs. open; unilateral vs. bilateral), surgical date, and destination (India or UAE)
• Complete required blood tests, cardiac clearance (ECG/ECHO), and anesthesia risk assessment — these may be performed locally and submitted digitally, or completed upon arrival
• Genetic counseling appointment scheduled if BRCA testing is indicated
• For premenopausal patients undergoing bilateral oophorectomy: fertility preservation consultation and cryopreservation arranged if desired
• GAF Healthcare initiates e-Medical visa application for India (typically approved within 1–3 business days) or confirms UAE entry requirements
• Pre-operative bowel preparation instructions and medication adjustments (anticoagulants, NSAIDs, hormone therapy) communicated by surgical team
PHASE 2 — ARRIVAL & PRE-OPERATIVE WORKUP (Day 1–2 in country)
• Airport pickup by GAF Healthcare's dedicated patient liaison team
• Hotel/hospital accommodation check-in; cultural and language interpreter assigned if required
• Day 1: In-person pre-operative consultation with the gynecologic surgeon; review of all imaging and pathology
• Day 1–2: Any outstanding diagnostics completed at the hospital (repeat ultrasound, blood work, cross-match for blood bank, anesthesia pre-assessment)
• Informed consent process: detailed discussion of surgical approach, intraoperative conversion risk, hormonal consequences of bilateral oophorectomy, and planned HRT regimen
• Nil by mouth (NPO) from midnight before surgery; low-residue diet and/or bowel preparation the day prior per surgeon protocol
PHASE 3 — SURGICAL DAY (Day 2–3)
• Admission to hospital 2–3 hours before scheduled operative time
• Pre-operative marking, sequential compression devices (SCDs) applied for DVT prophylaxis, IV access established
• General anesthesia induced; Foley catheter placed
• Laparoscopic/robotic/open oophorectomy performed per agreed surgical plan (operative time: 45–180 minutes depending on approach and complexity)
• Intraoperative frozen section histopathology performed if malignancy is suspected; definitive surgical staging adjusted accordingly
• Recovery room (PACU): 1–2 hours post-anesthesia monitoring; vital signs, pain assessment, IV analgesia (multimodal: paracetamol + ketorolac + opioid PRN)
• Transfer to inpatient ward upon hemodynamic stability
PHASE 4 — EARLY INPATIENT RECOVERY (Day 2–4 post-surgery)
• Laparoscopic/robotic cases: Clear liquid diet commenced Day 0 post-surgery; regular diet by Day 1. Urinary catheter removed within 12–24 hours. Ambulation encouraged from Day 1 per Enhanced Recovery After Surgery (ERAS) protocol.
• Open/cytoreductive cases: Nasogastric tube (if placed) removed when bowel function returns; diet advanced gradually. Catheter removed Day 2–3. Physiotherapy initiated Day 1.
• Pain managed with scheduled multimodal analgesia; PCA (patient-controlled analgesia) available for open cases
• DVT prophylaxis: low-molecular-weight heparin (LMWH — enoxaparin 40 mg SC once daily) from Day 1 post-surgery; continued for 28 days in cancer patients per ASCO guidelines
• Wound assessment; drain (if placed) output monitored
• Pathology report (definitive histology) typically available within 5–7 working days; oncology consultation scheduled if malignancy confirmed
• Discharge planning initiated; patient education on wound care, activity restrictions, and HRT initiation
PHASE 5 — EARLY POST-DISCHARGE RECOVERY (Week 1–3 in country)
• GAF Healthcare arranges comfortable hotel accommodation with nursing support availability
• Surgeon review appointment at Day 7: wound inspection, suture/staple removal (if non-absorbable), pathology discussion
• For bilateral oophorectomy patients: Initiation of hormone replacement therapy (HRT) — transdermal estradiol patch (Estradot 50–100 mcg/72h) or oral estradiol; progestogen added for patients with intact uterus. Bisphosphonate therapy (alendronate 70 mg weekly) and calcium/Vitamin D supplementation discussed.
• Vasomotor symptom management: SSNRIs (venlafaxine 37.5–75 mg/day) or gabapentin if HRT is contraindicated (e.g., hormone-receptor-positive breast cancer)
• Light walking encouraged from Day 3–5; no lifting >5 kg for 4 weeks (laparoscopic); 6–8 weeks (open)
• No driving until off opioid analgesia and reflexes fully restored (typically Day 7–14)
• No sexual intercourse for 4–6 weeks
PHASE 6 — FIT-TO-FLY ASSESSMENT & DEPARTURE
• Laparoscopic/robotic oophorectomy: Clearance for long-haul flight at 2–3 weeks post-surgery, provided no complications (wound infection, hematoma, ileus) are present. LMWH (compression stockings + enoxaparin) recommended for flights >4 hours.
• Open/cytoreductive surgery: Clearance at 4–6 weeks; enhanced DVT prophylaxis for air travel
• Final clinical summary, operative report, histopathology report, and medication prescriptions provided in English for continuity of care at home institution
• GAF Healthcare facilitates telemedicine follow-up at 6 weeks, 3 months, and 6 months post-discharge
MILESTONES SUMMARY:
• Return to light daily activities: 1–2 weeks (laparoscopic); 3–4 weeks (open)
• Return to desk work/remote employment: 2–3 weeks (laparoscopic); 4–6 weeks (open)
• Return to moderate exercise/gym: 6–8 weeks
• Full hormonal equilibration on HRT: 3–6 months
• Final oncology/pathology review and adjuvant therapy planning (if applicable): 3–4 weeks post-surgery
Risks & Considerations
Oophorectomy is a well-established surgical procedure with a favorable safety profile at high-volume centers, but all candidates must receive comprehensive informed consent regarding the following specific risks and considerations:
INTRAOPERATIVE RISKS: Hemorrhage from the infundibulopelvic or utero-ovarian ligament pedicles (incidence <2% at experienced centers); inadvertent ureteral injury — the ureter passes within 1–2 cm of the IP ligament and must be systematically identified before pedicle ligation (injury rate <0.5% with meticulous technique); bowel or bladder injury (risk elevated in cases with dense endometriotic adhesions or prior pelvic surgery); anesthetic complications; conversion from laparoscopic to open surgery in approximately 2–5% of cases due to bleeding, dense adhesions, or unexpected findings.
Top Hospitals for Oophorectomy (Ovarian Removal)
The following JCI and NABH-accredited hospitals are among the most experienced in specialist care, with dedicated teams and high-volume programmes.
Manipal Hospitals Dwarka
New Delhi, India
Burjeel Hospital for Advanced Surgery Dubai
Dubai, UAE
Kings College Hospital Dubai
Dubai, UAE
Aster Hospital Dubai
Dubai, UAE
Top Doctors for Oophorectomy (Ovarian Removal)
Internationally trained specialists in Gynecology. Review their profiles, compare experience, and connect directly through GAF Healthcare.
Dr. Tarang Preet Kaur
MBBS, MS, MRCOG, MCh, Fellowship in Urogynaecology, Fellowship in Cosmetic Gynaecology
Urogynaecologist
Max Super Speciality Hospital, Saket, New Delhi, India
11+ Yearsof experience
Dr. Tarang Preet Kaur is a Consultant in Urogynaecology with over 11 years of clinical experience, currently practicing at Max Super Speciality Hospital, Saket in New Delhi. She holds an MCh in Urogynaecology from Edge Hill University, United Kingdom (2024), the MRCOG from the Royal College of Obstetricians & Gynaecologists, and an MS in Obstetrics & Gynaecology from Maulana Azad Medical College, Delhi. Her dual qualification across India and the UK… Read more
Dr. Amrinder Kaur Bajaj
MBBS, MD — Obstetrics & Gynaecology (Gold Medalist), Senior Residency — Obstetrics & Gynaecology, FRSH — Fellow of the Royal Society of Health, FIAMS — Fellow of the Indian Association of Medical Specialists
Obstetrician & Gynaecologist
Fortis Hospital, Gurgaon, Gurgaon, India
42+ Yearsof experience
Dr. Amrinder Kaur Bajaj is one of Delhi-NCR's most experienced gynaecologists, with over four decades spent caring for women at every stage of life. She currently practises as a Consultant in Obstetrics & Gynaecology at Fortis Hospital, Gurgaon, where she brings together deep clinical knowledge and a quietly reassuring bedside manner that patients — and their families — find genuinely comforting. Her academic journey set a high bar early on. She completed… Read more
Dr. Anuradha Khurana
MBBS, DGO (Diploma in Obstetrics & Gynaecology), PG in High Risk Pregnancy and Infertility
Gynecologist & Obstetrics Specialist
Artemis Hospital, New Delhi, India
20+ Yearsof experience
Dr. Anuradha Khurana is a Senior Consultant in Obstetrics and Gynecology at Artemis Hospital, Delhi, with over two decades of hands-on experience in women's health. She is particularly well regarded for her work in high-risk pregnancy management, uterine conditions like fibroids and endometriosis, and complex gynecological surgeries. Patients and families consistently describe her as someone who takes the time to truly listen — and to explain things in a… Read more
Dr. Aswari Kesari Kapoor
MBBS, DGO (Diploma in Gynaecology & Obstetrics), CPS (College of Physicians and Surgeons), DNB (Diplomate of National Board) — Obstetrics & Gynaecology
Obstetrician & Gynecologist
Indraprastha Apollo Hospital, New Delhi, India
23+ Yearsof experience
Dr. Aswari Kesari Kapoor is a seasoned Obstetrician and Gynecologist with over 23 years of hands-on clinical experience. She practices at Indraprastha Apollo Hospital in New Delhi — one of India's most respected multi-specialty institutions. Over the course of her career, she has built a strong reputation for managing complex gynecological conditions alongside high-risk pregnancies, all with a calm and reassuring bedside manner that patients consistently… Read more
Dr. Bindhu K S
MBBS, DNB (Obstetrics & Gynecology), Fellowship in Minimal Access Surgery, FICOG (Fellowship of the Indian College of Obstetricians and Gynaecologists), Certificate in Gynecologic and Obstetric Sonography, Certificate in Appreciation of Well Being in Fetal Heart Disease
Obstetrician & Gynecologist
Apollo Hospitals, Navi Mumbai, Mumbai, India
23+ Yearsof experience
Dr. Bindhu K S is a seasoned Obstetrician and Gynecologist based in Mumbai, currently practicing at Apollo Hospitals, Navi Mumbai. With over two decades of clinical experience, she brings together expertise in both obstetrics and advanced minimally invasive gynecologic surgery. Whether a patient comes with a complex fibroid, troublesome endometriosis, or a high-risk pregnancy, Dr. Bindhu approaches each situation with careful thought and genuine care. Her… Read more
Frequently Asked Questions — Oophorectomy (Ovarian Removal)
The cost of oophorectomy varies by surgical approach, laterality (unilateral vs. bilateral), and whether oncologic staging is required. In India, laparoscopic or robotic oophorectomy at a JCI- or NABH-accredited hospital typically costs between USD 2,500 and USD 7,000 — inclusive of surgery, anesthesia, hospital stay of 1–3 days, standard medications, and post-operative ward care. Open or cytoreductive oophorectomy for advanced ovarian cancer in India may range from USD 5,000 to USD 7,000 for the primary surgical episode, with adjuvant chemotherapy (carboplatin + paclitaxel, 6 cycles) quoted separately at approximately USD 3,000–6,000. In the UAE (Dubai or Abu Dhabi), the same procedures at JCI- and DHA-accredited centers are estimated at USD 6,000–USD 16,000, reflecting the premium facility environment, higher operational costs, and the elevated cost of living in the Gulf region. This represents a cost saving of 50–65% for patients choosing India — without any compromise in surgical technique, technology (robotic platforms are available in both destinations), or accreditation standards. GAF Healthcare provides a personalized cost estimate within 48 hours of receiving a patient's medical records and imaging.
The minimum recommended in-country stay before international air travel depends on the surgical approach and complexity of your procedure. For laparoscopic or robotic-assisted oophorectomy (the most common approach for benign and early-stage conditions), most patients are cleared for long-haul flights 2–3 weeks after surgery, provided the recovery is uncomplicated — no wound infection, no bowel or urinary complications, and adequate pain control on oral analgesia only. For open oophorectomy or cytoreductive debulking surgery for ovarian cancer, the fit-to-fly period extends to 4–6 weeks post-operatively. All patients traveling by air after oophorectomy should wear graduated compression stockings (18–21 mmHg) and, for flights exceeding 4 hours, are advised to use low-molecular-weight heparin (LMWH) injections — particularly cancer patients, who carry a substantially elevated venous thromboembolism (VTE) risk. ASCO guidelines recommend LMWH prophylaxis for 28 days post-surgery in all gynecologic oncology patients. GAF Healthcare's surgical team conducts a formal fit-to-fly assessment before every international discharge and provides written clearance documentation, compression stocking prescriptions, and LMWH instructions to ensure safe travel.
At high-volume, subspecialty gynecologic surgery centers — the tier of hospital GAF Healthcare partners with in both India and the UAE — oophorectomy carries a procedural success rate of 95–98%, defined as complete surgical removal of the target pathology without major intraoperative complications. For benign conditions such as dermoid cysts, endometrioma, or simple ovarian cysts, laparoscopic or robotic oophorectomy is curative in the overwhelming majority of cases, with recurrence rates below 10–15% for endometrioma over a 5-year follow-up period. For risk-reducing salpingo-oophorectomy (RRSO) in BRCA1/BRCA2 mutation carriers, evidence demonstrates an 80–96% reduction in lifetime ovarian cancer risk and approximately 50% reduction in breast cancer risk (BRCA1 carriers), making it one of the most effective cancer prevention interventions available. For epithelial ovarian carcinoma, surgical outcomes are most closely correlated with the degree of cytoreduction achieved: patients achieving optimal debulking (R0 — no visible residual disease) demonstrate a median overall survival of 4–5 years for Stage IIIC disease, compared to approximately 2–3 years with suboptimal debulking. Five-year survival rates for early-stage (FIGO Stage I) ovarian cancer following complete surgical staging exceed 85–90%. All outcome data is reviewed transparently with patients during pre-operative consultation, and GAF Healthcare's partner surgeons provide individualized prognosis estimates based on each patient's specific tumor histology, grade, and staging.
Why Plan Your Treatment Through Gaf Healthcare?
GAF Healthcare provides comprehensive end-to-end non-medical support for international patients traveling to India or the UAE for oophorectomy, ensuring that the logistical burden of medical travel is fully managed so patients and their families can focus entirely on treatment and recovery.
INDIA — VISA & ENTRY: GAF Healthcare facilitates the Indian e-Medical Visa (eMV) application on behalf of the patient and one accompanying attendant. The eMV is available to citizens of over 150 countries, is processed entirely online, and is typically approved within 1–5 business days. It permits a stay of up to 60 days (triple-entry). Patients requiring an extended stay (e.g., post-cytoreductive surgery with adjuvant chemotherapy) are guided through the Medical Visa (paper) application process via the Indian Embassy, which permits stays of up to 1 year. GAF Healthcare provides the official hospital invitation letter required for both visa types.
UAE — VISA & ENTRY: Citizens of GCC member states and over 50 nationalities (including the UK, US, EU, and Australia) receive a visa-free or visa-on-arrival entry for 30–90 days in the UAE, making it logistically straightforward for a broad international patient base. For nationalities requiring a pre-arranged visa, GAF Healthcare coordinates a medical visit visa through the hospital's international patient services department or the UAE Embassy in the patient's country. Dubai's Dubai Health Authority (DHA) and Abu Dhabi's Department of Health oversee accreditation of all partner facilities.
AIRPORT TRANSFERS & IN-COUNTRY TRANSPORT: Dedicated, air-conditioned private vehicles with professional drivers meet patients at Indira Gandhi International (Delhi), Chhatrapati Shivaji Maharaj International (Mumbai), Chennai International, or other arrival airports in India, and at Dubai International (DXB), Al Maktoum International (DWC), or Abu Dhabi International (AUH) in the UAE. Wheelchair-accessible vehicles are arranged on request. All inter-city transfers, hospital commutes, and post-discharge medical appointment transport are coordinated and pre-scheduled by the GAF Healthcare patient liaison team.
DEDICATED PATIENT LIAISON & TRANSLATION: Each patient is assigned a named GAF Healthcare Patient Coordinator who is reachable via WhatsApp, phone, and email throughout the treatment journey — from pre-travel document submission to post-discharge telemedicine follow-up. Professional medical interpreters are available in Arabic, Russian, French, Swahili, Bengali, and other languages at hospitals in both India and the UAE. Interpreter services are arranged in advance for all clinical consultations, surgical consent discussions, and pathology review meetings.
ACCOMMODATION FOR PATIENT & ATTENDANT: GAF Healthcare has pre-negotiated preferential rates at partner hotels and serviced apartments within 2–5 km of all major hospital facilities in both destinations. Options range from comfortable 3-star accommodation with kitchenette facilities (suitable for longer stays during recovery) to 5-star properties adjacent to hospital campuses. Attendant accommodation within the hospital room is arranged for the inpatient stay where hospital policy permits. For patients undergoing bilateral oophorectomy who require in-room nursing support during the immediate post-discharge period, GAF Healthcare can arrange a private registered nurse for home/hotel visits.
TELEMEDICINE & POST-RETURN FOLLOW-UP: All patients receive a structured teleconsultation schedule with their treating surgeon at 2 weeks, 6 weeks, 3 months, and 6 months post-surgery. Digital copies of the complete medical record — operative report, histopathology, discharge summary, imaging, and prescriptions — are provided via a secure patient portal within 24 hours of discharge to facilitate seamless handover to the patient's home-country physician.